GSK »

Regenxbio Inc equity us cm shares owned by GSK

Quarter-by-quarter ownership of Regenxbio Inc equity us cm (RGNX) shares owned by GSK from 13F filings

Historical chart of GSK investment in Regenxbio Inc equity us cm

Tip: Access up to 7 years of quarterly data

All positions including Regenxbio Inc equity us cm held by GSK consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Regenxbio Inc equity us cm by GSK

Quarter filed Position value Share count Share price at filing
2026-06-30 $3.3M 272k 11.98

More positions owned by GSK

Crispr Therapeutics Namen Akt (CRSP)
Wave Life Sciences SHS (WVE)
Vir Biotechnology (VIR)
Biontech Se Sponsored Ads (BNTX)
Ideaya Biosciences (IDYA)
Cytokinetics Com New (CYTK)
Lyell Immunopharma Com New (LYEL)
Spero Therapeutics (SPRO)
Nkarta (NKTX)
Fulcrum Therapeutics (FULC)
Bicycle Therapeutics Sponsored Ads (BCYC)
CVRX (CVRX)
Regenxbio Inc equity us cm (RGNX)

View all positions for GSK

Top funds holding Regenxbio Inc equity us cm

BlackRock
Redmile Group
State Street Corporation
Jpmorgan Chase & Co
Vanguard Capital Management
Morgan Stanley
Goldman Sachs Group
Integral Health Asset Management
Vanguard Portfolio Management
Qube Research & Technologies
Marshall Wace
Geode Capital Management
AQR Capital Management
Dimensional Fund Advisors
Nuveen

View all funds holding Regenxbio Inc equity us cm